SCHEMBL4492290

SCHEMBL4492290

Nc1ccc2c(c1)C(=O)N1CCC[C@H]1CO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 4/20 0.42
CHRNA3 P32297 4/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
GRIA1 P42261 1/20 0.42
AR P10275 2/20 0.38
ALDH1A1 P00352 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ALPL P05186 2/20 0.36
CRBN Q96SW2 2/20 0.36
AXL P30530 3/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
DGAT1 O75907 1/20 0.34
GFER P55789 1/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5986573 0.84 CYP19A1 (0.45) GRIA1ARALPLMEN1KMT2A
SCHEMBL4489627 0.84 CYP19A1 (0.45) GRIA1ARALPLMEN1KMT2A
SCHEMBL4485924 0.84 CYP19A1 (0.45) GRIA1ARALPL
SCHEMBL4484219 0.84 CYP19A1 (0.45) GRIA1ARALPLMEN1KMT2A
SCHEMBL4495801 0.84 CYP19A1 (0.45) GRIA1ARALPL
SCHEMBL4498044 0.84 ALPL (0.46) GRIA1ARALPL
SCHEMBL4495976 0.82 HTR1A (0.41) GRIA1ARALDH1A1ALPLAXL
SCHEMBL4559306 0.82 HTR1A (0.41) GRIA1ARALDH1A1ALPLAXL
SCHEMBL4489951 0.81 HTR2A (0.46) GRIA1ARALDH1A1ALPLLMNA
SCHEMBL4484222 0.81 KMT2A (0.46) GRIA1ARALDH1A1ALPLGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504390-B2 Benzoxazepine derivatives and their use as AMPA receptor stimulators N.V. ORGANON (NL) 2009-03-17 US disclosed
US-20080139529-A1 BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS N.V. ORGANON (NL) 2008-06-12 US disclosed
EP-1399450-B1 BENZOXAZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS ORGANON NV (NL) 2008-03-19 EP disclosed
US-7307073-B2 Benzoxazepines derivatives and their use as AMPA receptor stimulators N.V. ORGANON (NL) 2007-12-11 US disclosed
US-20040171605-A1 Benzoxazepines derivatives and their use as ampa receptor stimulators MERCK SHARP & DOHME B.V. (NL) 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171605-A1 Benzoxazepines derivatives and their use as ampa receptor stimulators CHRNA4, CHRNA10, CHRNA9 CHRNB4 43/4885CHRNA3 21/4885CHRNB2 56/4885
US-20080139529-A1 BENZOXAPZEPINE DERIVATIVES AND THEIR USE AS AMPA RECEPTOR STIMULATORS GRIN1, GRIA4, CHRNA4 CHRNB4 50/4885CHRNA3 34/4885CHRNB2 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.